BioIntelliSense Unveils Rechargeable BioButton

BioIntelliSense has released a rechargeable version of its BioButton wearable for remote patient monitoring. The original BioButton debuted in May of 2020, but is designed to be disposed of after a period of 90 days.

The BioButton Rechargeable, on the other hand, can be worn indefinitely. The device can run for up to 16 days on a single charge, and is ideal for long-term care situations in which patients need to monitor their vital signs for months or years at a time, if only because it ensures that people will not need to worry about replacing their BioButton at regular intervals.

In terms of overall utility, the BioButton Rechargeable is comparable to its predecessor. The device can passively track more than 20 key vital signs, and can take as many as 1,440 measurements per day. In doing so, it provides doctors with far more insight into a patient’s condition in real time, and allows them to respond more quickly in the event of an emergency. In that regard, BioIntelliSense’s platform comes with a series of algorithms that will send an immediate notification if changes in someone’s vitals point to a potential crisis.

The BioButton Rechargeable can serve as an early warning system, and can track everything from heart rate and temperature to body position and gait. It also negates the need for time-consuming manual health checks throughout the day, making it a good option when doctors want to keep tabs on a patient’s health after they have left the hospital.

“Our commitment to making remote patient care ubiquitous and scalable is further advanced with the introduction of the BioButton Rechargeable device,” said BioIntelliSense CEO and Founder James Mault. “The BioButton Rechargeable is realizing a new standard in remote care that is effortless for the patient and clinician, while allowing providers to scale care without scaling costs.”

BioIntelliSense has provided remote monitoring services for multiple healthcare organizations during the pandemic, most recently delivering biometric wearables for Mubadala Health in the United Arab Emirates. The company also raised $45 million in Series B funding in 2021.

–

March 16, 2022 – by Eric Weiss